Zurcher Kantonalbank (Zurich Cantonalbank) Avidity Biosciences, Inc. Transaction History

Zurcher Kantonalbank (Zurich Cantonalbank)

$32.8 Billion
Q3 2024

A detailed history of Zurcher Kantonalbank (Zurich Cantonalbank) transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Zurcher Kantonalbank (Zurich Cantonalbank) holds 21,370 shares of RNA stock, worth $883,649. This represents 0.0% of its overall portfolio holdings.

Number of Shares

21,370

Previous 21,370 -0.0%

Holding current value

$883,649

Previous $981,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 07, 2024	SELL	$37.21 - $48.14 $33,749 - $43,662	-907 Reduced 4.07%	21,370 $981,000
Q2 2024 Jul 29, 2024	BUY	$22.73 - $40.85 $164,974 - $296,489	7,258 Added 48.33%	22,277 $910,000
Q1 2024 Apr 25, 2024	BUY	$9.16 - $25.52 $32,527 - $90,621	3,551 Added 30.96%	15,019 $383,000
Q4 2023 Jan 30, 2024	SELL	$4.87 - $9.37 $886 - $1,705	-182 Reduced 1.56%	11,468 $103,000
Q3 2023 Oct 25, 2023	SELL	$6.3 - $11.35 $793 - $1,430	-126 Reduced 1.07%	11,650 $74,000
Q2 2023 Aug 07, 2023	BUY	$10.62 - $17.34 $17,034 - $27,813	1,604 Added 15.77%	11,776 $130,000
Q1 2023 May 08, 2023	BUY	$15.35 - $25.65 $2,087 - $3,488	136 Added 1.36%	10,172 $156,000
Q4 2022 Feb 01, 2023	BUY	$10.06 - $22.66 $46,819 - $105,459	4,654 Added 86.47%	10,036 $222,000
Q2 2022 Aug 09, 2022	SELL	$11.18 - $20.5 $1,118 - $2,050	-100 Reduced 1.82%	5,382 $78,000
Q1 2022 Apr 21, 2022	BUY	$14.2 - $23.78 $18,516 - $31,009	1,304 Added 31.21%	5,482 $101,000
Q3 2021 Nov 15, 2021	BUY	$18.16 - $25.21 $75,872 - $105,327	4,178 New	4,178 $103,000

Others Institutions Holding RNA

# of Institutions

256

Shares Held

107M

Call Options Held

224K

Put Options Held

161K

View Full List

About Avidity Biosciences, Inc.

Ticker RNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,127,000
Market Cap $2.16B
Description
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...

More about RNA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Zurcher Kantonalbank (Zurich Cantonalbank), based on Form 13F filings with the SEC.

News

Stay updated on Zurcher Kantonalbank (Zurich Cantonalbank) with notifications on news.

Account

Zurcher Kantonalbank (Zurich Cantonalbank) Avidity Biosciences, Inc. Transaction History